Légende
: Essai en cours de recrutement = 
; Essai en cours = 
-
- ALLEMAGNE
- Baden-Württemberg
- FREIBURG
- MDS Low-Dose-Decitabine (EORTC-06011): Intravenous low-dose Decitabine versus Supportive Care in elderly patients with primary Myelodysplastic Syndrome (MDS), secondary MDS or Chronic Myelomonocytic Leukemia (CMML) who are not eligible for intensive therapy: An EORTC-German MDS study group randomized phase III study
- Universitätsklinikum Freiburg
- Abteilung Innere Medizin I - Hämatologie und Onkologie
- Plus de détails
-
- ALLEMAGNE
- Baden-Württemberg
- MANNHEIM
- A survival study in patients with high risk Myelodysplastic Syndromes comparing Azacitidine versus Conventional Care (Phase III) - Terminated
- Universitätsklinikum Mannheim
- III. Medizinische Klinik
- Plus de détails
-
- ALLEMAGNE
- Baden-Württemberg
- MANNHEIM
- CC-5013-MDS-005: A Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of Lenalidomide versus Placebo in subjects with transfusion dependent Anemia due to low or intermediate risk MDS without Del 5Q and unresponsive to erythropoiesis-stimulating agents
- Universitätsklinikum Mannheim
- III. Medizinische Klinik
- Plus de détails
-
- ALLEMAGNE
- Baden-Württemberg
- MANNHEIM
- MDS Exjade: A One-year, open-label, single Arm, multicenter phase IV trial evaluating the efficacy and safety of oral ICL670 in patients with Low and INT-1 risk Myelodysplastic Syndrome (MDS) and Transfusion-dependent Iron Overload - Terminated
- Universitätsklinikum Mannheim
- III. Medizinische Klinik
- Plus de détails
-
- ALLEMAGNE
- Baden-Württemberg
- STUTTGART
- EORTC 06023: Randomized Phase II Trial With Infliximab (Remicade) in Patients With Myelodysplastic Syndrome and a Relatively Low Risk of Developing Acute Leukemia (Phase II) - Terminated
- Marienhospital Stuttgart
- Zentrum für Innere Medizin III - Onkologie, Hämatologie, Palliativmedizin
- Plus de détails
-
- ALLEMAGNE
- Baden-Württemberg
- TÜBINGEN
- Phase I/II study of haploidentical hematopoietic cell transplantation with CD3/CD19 depleted grafts in patients with treatment refractory hematologic malignancies
- Universitätsklinikum Tübingen
- Medizinische Klinik Abteilung II - Hämatologie, Onkologie und Pulmologie
- Plus de détails
-
- ALLEMAGNE
- Bayern
- ERLANGEN
- Exjade-Early-Trial: Early treatment with Deferasirox in low risk MDS - A prospective multicentre single-arm single-stage Phase II Study
- Universitätsklinikum Erlangen
- Medizinische Klinik 5
- Plus de détails
-
- WT1 Vaccination: Phase II Study of WT1 126-134 Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in AML - Terminated
- Charité - Universitätsmedizin Berlin (CBF)
- Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie (CBF)
- Plus de détails
-
- ALLEMAGNE
- Hamburg
- HAMBURG
- RICMAC - A randomized phase III study: dose-reduced versus standard conditioning followed by allogenic stem cell transplantation in patients with myelodysplastic syndrome or secondary acute myeloid leukemia - DE
- Universitätsklinikum Hamburg-Eppendorf
- Interdisziplinäre Klinik und Poliklinik für Stammzelltransplantation
- Plus de détails
-
- ALLEMAGNE
- Niedersachsen
- HANNOVER
- MDS Romiplostim: A randomized, double blind, placebo controlled study evaluating the efficacy and safety of romiplostim treatment of thrombocytopenia in subjects with low or intermediate-1 risk myelodysplastic syndrome (MDS) - Terminated
- Medizinische Hochschule Hannover
- Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation
- Plus de détails
-
- ALLEMAGNE
- Niedersachsen
- HANNOVER
- ClAraC-SCT: Randomized, multicentre, phase II trial to compare the event-free survival of Clofarabine / Ara-C (ClAraC) or of FLAMSA treatment in patients with high risk AML or advanced MDS scheduled for allogeneic stem cell transplantation
- Medizinische Hochschule Hannover
- Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation
- Plus de détails
-
- ALLEMAGNE
- Nordrhein-Westfalen
- DÜSSELDORF
- Phase-II trial to assess the efficacy and toxicity of 5-Azacitidine in addition to standard donor lymphocyte for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome relapsing after allogeneic stem cell transplantation
- Universitätsklinikum Düsseldorf
- Klinik für Hämatologie, Onkologie und Klinische Immunologie
- Plus de détails
-
- ALLEMAGNE
- Nordrhein-Westfalen
- DÜSSELDORF
- Valena-Study: Phase II study for the determination of efficacy and tolerability of the combination of valproic acid and lenalidomide in the treatment of MDS patients with favorable risk profile.
- Universitätsklinikum Düsseldorf
- Klinik für Hämatologie, Onkologie und Klinische Immunologie
- Plus de détails
-
- ALLEMAGNE
- Nordrhein-Westfalen
- DÜSSELDORF
- MDS/AML Eltrombopag: a phase I/II study of Eltrombopag in thrombocytopenic subjects with advanced MyeloDysplastic Syndrome (MDS) or secondary Acute Myeloid Leukemia after MDS - DE
- Universitätsklinikum Düsseldorf
- Klinik für Hämatologie, Onkologie und Klinische Immunologie
- Plus de détails
-
- ALLEMAGNE
- Nordrhein-Westfalen
- DÜSSELDORF
- EPOANE: A randomized, double-blind, placebo-controlled, multicenter phase III study evaluating Epoetin Alfa versus Placebo in anemic Patients with IPSS low- or intermediate-1-risk Myelodysplastic Syndrom - DE
- Universitätsklinikum Düsseldorf
- Klinik für Hämatologie, Onkologie und Klinische Immunologie
- Plus de détails
-
- ALLEMAGNE
- Nordrhein-Westfalen
- ESSEN
- Clinical Phase III Trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic Stem Cell Transplantation in patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) considered ineligible to standard conditioning regimens - DE
- Universitätsklinikum Essen
- Klinik für Knochenmarktransplantation
- Plus de détails
-
- ALLEMAGNE
- Sachsen
- DRESDEN
- AML 2003: Randomized comparison between standard-therapy and intensified therapy for adult Acute Myeloid Leukemia patients <= 60 Years (Phase IV)
- Universitätsklinikum Carl Gustav Carus der TU Dresden
- Medizinische Klinik und Poliklinik I
- Plus de détails
-
- ALLEMAGNE
- Sachsen
- DRESDEN
- TUD-LENAMA-022: Lenalidomide maintenance therapy in patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukaemia (AML) - Phase II study - Terminated
- Universitätsklinikum Carl Gustav Carus der TU Dresden
- Medizinische Klinik und Poliklinik I
- Plus de détails
-
- ALLEMAGNE
- Sachsen
- DRESDEN
- TUD-RELAZA-008: Treatment of the haematological relapse in patients with AML and MDS following allogenic Stem Cell Transplantation with 5-Azacitidine (Vidaza®) (Phase III) - Terminated
- Universitätsklinikum Carl Gustav Carus der TU Dresden
- Medizinische Klinik und Poliklinik I
- Plus de détails
-
- ALLEMAGNE
- Sachsen
- DRESDEN
- GEPARD Study: A One Year, open label, multicenter trial of LBH589 alone or in combination with ESA in red blood cell transfusion-dependent LOW and INT-1 MDS patients being either refractory to ESA or with a low probability of response
- Universitätsklinikum Carl Gustav Carus der TU Dresden
- Medizinische Klinik und Poliklinik I
- Plus de détails
-
- ALLEMAGNE
- Sachsen
- DRESDEN
- RELAZA2 (TUD-RELA02-048): Treatment of patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) with an impending hematological relapse with Azacitidin (Phase II)
- Universitätsklinikum Carl Gustav Carus der TU Dresden
- Medizinische Klinik und Poliklinik I
- Plus de détails
-
- ESPAGNE
- Castilla - León
- SALAMANCA
- SIMIDIS: A Multicenter, Non-Randomized, Open-Label Study to Evaluate Efficacy and Safety of Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome Red Cell Transfusion Dependent With Low or Intermediate -1 Risk (Phase II)
- Complejo Asistencial Universitario de Salamanca
- Servicio de Hematología
- Plus de détails
-
- ESPAGNE
- Cataluña
- BARCELONA
- MDS Romiplostim : A randomized, double blind, placebo controlled study evaluating the efficacy and safety of romiplostim treatment of thrombocytopenia in subjects with low or intermediate-1 risk myelodysplastic syndrome (MDS) (Phase II) - ES (terminated)
- Hospital Universitari General Vall d'Hebron
- Servicio de Hematología
- Plus de détails
-
- ESPAGNE
- Cataluña
- BARCELONA
- A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy (Phase II/III) - ES
- Hospital de la Santa Creu i Sant Pau
- Servicio de Hematología Clínica
- Plus de détails
-
- ESPAGNE
- Comunidad Valenciana
- VALENCIA
- A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy (Phase II/III) - ES
- Hospital Clínico Universitario de Valencia
- Servicio de Hematología y Oncología Médica
- Plus de détails
-
- ESPAGNE
- Comunidad Valenciana
- VALENCIA
- Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q- Abnormality (completed)
- Hospital Universitario y Politécnico La Fe
- Servicio de Hematología y Hemoterapia
- Plus de détails
-
- ESPAGNE
- Comunidad Valenciana
- VALENCIA
- A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy (Phase II/III) - ES
- Hospital Universitario y Politécnico La Fe
- Servicio de Hematología y Hemoterapia
- Plus de détails
-
- ESPAGNE
- Comunidad Valenciana
- VALENCIA
- SIMIDIS: A Multicenter, Non-Randomized, Open-Label Study to Evaluate Efficacy and Safety of Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome Red Cell Transfusion Dependent With Low or Intermediate -1 Risk (Phase II)
- Hospital Universitario y Politécnico La Fe
- Servicio de Hematología y Hemoterapia
- Plus de détails
-
- ESPAGNE
- Madrid
- NOT YET IDENTIFIED - ES
- An Open Label Extension Study Evaluating the Safety of Long Term Dosing of Romiplostim in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS) - ES (Completed)
- Not yet identified - ES
- Plus de détails
-
- ESPAGNE
- Madrid
- NOT YET IDENTIFIED - ES
- A multicenter, randomised, double-blind, placebo-controlled study of Darbepoetin Alfa for the treatment of anaemic subjects with low or intermediante-1 risk myelodysplastic syndrome (MDS) - ES (Phase III)
- Not yet identified - ES
- Plus de détails
-
- ESPAGNE
- Madrid
- NOT YET IDENTIFIED - ES
- A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Subjects With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome - ES (terminated)
- Not yet identified - ES
- Plus de détails
-
- ESPAGNE
- Madrid
- NOT YET IDENTIFIED - ES
- A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) - ES
- Not yet identified - ES
- Plus de détails
-
- ESPAGNE
- Madrid
- NOT YET IDENTIFIED - ES
- ASTEROID: A Multicenter, Randomized, Comparative Study of Different Deferasirox Administration Regimens on Gastrointestinal (GI) Tolerability in Low or Intermediate (Int-1) Risk MDS Myelodysplastic Syndrome Patients With Transfusional Iron Overload (Phase IV) - ES (completed)
- Not yet identified - ES
- Plus de détails
-
- ESPAGNE
- País Vasco
- VITORIA - GASTEIZ
- Phase II Clinical Trial for Treatment of Myelodysplastic Syndromes Comparing Hydralazine / Ac.Valproico and Supportive Care in Patients Not Candidates, Refractory and / or Intolerant to Intensive Chemotherapy
- Hospital de Txagorritxu
- Servicio de Hematología (H. Txagorritxu)
- Plus de détails
-
- FINLANDE
- Finland
- HELSINKI
- Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens - FI -
- HUCH - Helsinki University Central Hospital
- Deparment of Medicine
- Plus de détails
-
- FRANCE
- ILE-DE-FRANCE
- BOBIGNY
- Lenalidomide versus placebo dans les syndromes myélodysplasiques associés à la délétion 5q (Phase III)
- CHU Paris Seine-Saint-Denis - Hôpital Avicenne
- Service d'hématologie clinique
- Plus de détails
-
- FRANCE
- ILE-DE-FRANCE
- BOBIGNY
- Essai de phase II évaluant l'efficacité et la tolérance du lénalidomide combiné à l'azacitidine chez les patients présentant un syndrome myélodysplasique de risque intermédiaire 2 ou élevé ou une leucémie aiguë myéloblastique, avec une délétion 5q31.
- CHU Paris Seine-Saint-Denis - Hôpital Avicenne
- Service d'hématologie clinique
- Plus de détails
-
- FRANCE
- ILE-DE-FRANCE
- BOBIGNY
- GFM-Erlotinib-08 - Essai de phase I-II évaluant la toxicité et l'efficacité de l'erlotinib chez les patients présentant un syndrome myélodysplasique de risque intermédiaire 2 ou élevé.
- CHU Paris Seine-Saint-Denis - Hôpital Avicenne
- Service d'hématologie clinique
- Plus de détails
-
- FRANCE
- ILE-DE-FRANCE
- BOBIGNY
- NIDEVOL - Etude multicentrique de phase I/II de clofarabine iv chez des patients ayant un syndrome myélodysplasique de haut risque en échec d'azacitidine.
- CHU Paris Seine-Saint-Denis - Hôpital Avicenne
- Service d'hématologie clinique
- Plus de détails
-
- FRANCE
- ILE-DE-FRANCE
- BOBIGNY
- Étude de phase I-II de l'association d'idarubicine et d'azacitidine dans le traitement des syndromes myélodysplasiques de risque élevé et intermédiaire 2.
- CHU Paris Seine-Saint-Denis - Hôpital Avicenne
- Service d'hématologie clinique
- Plus de détails
-
- FRANCE
- ILE-DE-FRANCE
- BOBIGNY
- AZA-PLUS - Essai thérapeutique randomisé de Phase II à la recherche de l'association la plus prometteuse avec l'azacytidine (AZA) dans les syndromes myélodysplasiques de haut risque.
- CHU Paris Seine-Saint-Denis - Hôpital Avicenne
- Service d'hématologie clinique
- Plus de détails
-
- FRANCE
- ILE-DE-FRANCE
- PARIS
- Etude de phase II comparant le traitement par lénalidomide (Revlimid®) ou lénalidomide (Revlimid®) et époetin bêta (Neorecormon®) dans les syndromes myélodysplasiques de risque faible ou int-1 selon l'index IPSS non 5q chez les patients transfusés et résistant aux agents stimulant l'érythropoièse (ESA).
- CHU Paris Centre - Hôpital Cochin
- Service d'hématologie clinique
- Plus de détails
-
- FRANCE
- ILE-DE-FRANCE
- PARIS
- 5-Azacitidine, acide valproïque et acide rétinoïque dans la leucémie aigue myéloïde et les syndromes myélodysplasiques de haut risque (Phase II) - Terminé -
- CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
- Maladies du sang
- Plus de détails
-
- FRANCE
- ILE-DE-FRANCE
- VILLEJUIF
- (APL-A-005-02) Etude de phase I/II clinique et pharmacocinétique de Aplidin (APL) administré en PIV de 3 heures toutes les 2 semaines chez des enfants atteints de tumeurs malignes et de leucémies réfractaires ou récidivantes - Terminé -
- CRLCC Institut de cancérologie Gustave Roussy
- Département de cancérologie de l'enfant et de l'adolescent
- Plus de détails
-
- FRANCE
- PAYS DE LA LOIRE
- NANTES
- Cloric : Essai de Phase II, en ouvert, multicentrique, non randomisé, évaluant l'efficacité et la tolérance de la Clofarabine en association avec le Busulfan (IV) et la Thymoglobuline (CBT) en tant que conditionnement avant une greffe de cellules souches allogéniques chez des patients adultes atteints de LAM, LAL ou de syndromes myélodysplasiques
- CHU de Nantes - Hôtel Dieu
- Service d'hématologie clinique
- Plus de détails
-
- FRANCE
- PAYS DE LA LOIRE
- NANTES
- GFM-EPO-QoL : Traitement de l'anémie des syndromes myélodysplasiques de faible risque par l'Epoétine Bêta avec analyse du retentissement sur la qualité de vie et les capacités fonctionnelles du patient (Phase II)
- CHU de Nantes - Hôtel Dieu
- Service d'hématologie clinique
- Plus de détails
-
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- Essai clinique de phase III comparant la thérapie de conditionnement à base de Tréosulfan avec un conditionnement à intensité réduite (CIR) à base de Busulfan, préalablement à la transplantation allogénique de cellules souches hématopoïétiques, chez les patients atteints de LAM ou du syndrome myélodysplasique (SMD), considérés comme inéligibles aux régimes de conditionnement standard
- Not yet identified - FR
- Plus de détails
-
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- Etude de phase I/II de l'eltrombopag chez des patients présentant une thrombocytopénie et atteints d'un syndrome myélodysplasique avancé (MDS) ou d'une leucémie aiguë myéloïde secondaire à un MDS (sAML/MDS) (Protocole PMA112509).
- Not yet identified - FR
- Plus de détails
-
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- GFM-Aza intensif : A phase I/II study of the efficacy and safety of an intensified schedule of Azacitidine (Vidaza®) in intermediate-2 and high risk MDS patients - FR
- Not yet identified - FR
- Plus de détails
-
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- GFM-Aza-ceplene : A phase I study of azacitidine with Ceplene/interleukin-2 followed by a randomized phase II study of the efficacy and safety of maintenance treatment with azacitidine with or without Ceplene/interleukin-2 in patients with higher risk myelodysplastic syndromes who achieved hematological response to azacitidine - FR
- Not yet identified - FR
- Plus de détails
-
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- A Phase I dose-escalation study of IPH2102, a fully human anti-KIR monoclonal antibody (CHO manufacturing), in patients with various hematologic or solid malignancies - FR
- Not yet identified - FR
- Plus de détails
-
- ITALIE
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- Clinical phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens
- NOT YET IDENTIFIED - IT
- Plus de détails
-
- Clinical Phase III Trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic Stem Cell Transplantation in patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) considered ineligible to standard conditioning regimens
- Ospedali Riuniti di Bergamo
- U.O. di Ematologia
- Plus de détails
-
- Multicenter Phase II Study of Haploidentical Hematopoietic Cell Transplantation With CD3/CD19 Depleted Grafts After a Reduced Intensity Conditioning Regimen for Adult Patients With Acute Leukemia
- IRCCS Ospedale San Raffaele - DIBIT
- Dipartimento di Ematologia
- Plus de détails
-
- PAYS-BAS
- Gelderland
- NIJMEGEN
- Randomized study with young MDS patients with a 5-20% blast in bonemarrow before allogene stem cell transplantation (allo-SCT), comparison of allo-SCT with stem cells from peripheral blood or bonemarrow
- UMC St Radboud - Universitair Medisch Centrum St Radboud
- Afdeling Hematologie
- Plus de détails
-
- PAYS-BAS
- Gelderland
- NIJMEGEN
- A Multicenter, Randomized, Open-label, Parallel-group, Phase 3 Trial of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes
- UMC St Radboud - Universitair Medisch Centrum St Radboud
- Afdeling Hematologie
- Plus de détails
-
- PAYS-BAS
- Gelderland
- NIJMEGEN
- Idarubicin and Cytarabine in combination with Gemtuzumab Ozogamicin (IAGO) for young untreated patients without HLA identical familial donor with high risk developing MDS/AML after 6 months of the diagnosis MDS
- UMC St Radboud - Universitair Medisch Centrum St Radboud
- Afdeling Hematologie
- Plus de détails
-
- PAYS-BAS
- Gelderland
- NIJMEGEN
- RICMAC: Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem Cell Transplantation in Patients With MDS or sAML: A Randomised Phase III Study
- UMC St Radboud - Universitair Medisch Centrum St Radboud
- Afdeling Tumor Immunologie
- Plus de détails
-
- PAYS-BAS
- Gelderland
- NIJMEGEN
- A single center, Phase I/II Clinical Trial to study the safety of treatment with CP-675,206 or Ticilimumab (antiCTLA-4) in patients with low risk myelodysplastic syndrome (MDS)
- UMC St Radboud - Universitair Medisch Centrum St Radboud
- Afdeling Tumor Immunologie
- Plus de détails
-
- PAYS-BAS
- Gelderland
- NIJMEGEN
- A Prospective Randomized Phase-III Clinical Trial to evaluate the effect of treatment with Aranesp ± Neupogen in patients with myelodysplastic syndrome (MDS)
- UMC St Radboud - Universitair Medisch Centrum St Radboud
- Afdeling Tumor Immunologie
- Plus de détails
-
- PAYS-BAS
- Gelderland
- NIJMEGEN
- A phase 2 clinical trial to evaluate the feasibility of treatment with Aranesp in patients with myelodysplastic syndrome (MDS)
- UMC St Radboud - Universitair Medisch Centrum St Radboud
- Afdeling Tumor Immunologie
- Plus de détails
-
- PAYS-BAS
- Zuid-Holland
- DEN HAAG
- Intravenous Low-Dose Decitabine Versus Supportive Care in Elderly Patients With Primary Myelodysplastic Syndrome (MDS) (>10% Blasts or High-Risk Cytogenetics), Secondary MDS or Chronic Myelomonocytic Leukemia (CMML) Who Are Not Eligible for Intensive Therapy: An EORTC-German MDS Study Group Randomized Phase III Study
- Haga Ziekenhuis, locatie Leyenburg
- Afdeling Haematologie
- Plus de détails
-
- PAYS-BAS
- Zuid-Holland
- ROTTERDAM
- Lenalidomide Versus Placebo in Myelodysplastic Syndromes with an Deletion-5q Abnormality
- Erasmus MC - Erasmus Medisch Centrum
- Afdeling Hematologie
- Plus de détails
-
- ROYAUME-UNI
- Greater London
- LONDON
- An open-label, uncontrolled, multicenter, multinational study on the efficacy and safety of administration of donor lymphocytes depleted of alloreactive T-cells (ATIR), through the use of TH9402 and light treatment in an ex vivo process, in patients receiving a CD34-selected peripheral blood stem cell graft from a related, haploidentical donor (Phase II/III) - UK
- Faculty of Medicine - Imperial College of London
- Centre for Haematology
- Plus de détails
-
- ROYAUME-UNI
- Greater Manchester
- MANCHESTER
- APL-A-005-02: Phase I - II clinical and pharmacokinetic study of Aplidin (APL) as a 3-hour intravenous infusion every 2 weeks, in children with refractory or relapsed malignant tumours and leukaemia
- Royal Manchester Children's Hospital
- Department of Paediatric Oncology
- Plus de détails
-
- ROYAUME-UNI
- South Glamorgan
- CARDIFF
- AML 16: A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (PhaseII/III)
- Cardiff University School of Medicine
- Department of Medical Genetics, Haematology & Pathology
- Plus de détails
-
- ROYAUME-UNI
- South Glamorgan
- CARDIFF
- AML 17: Randomised, controlled, open label, multi-arm trial looking at treatment for acute promyelocytic leukaemia (Phase III)
- Cardiff University School of Medicine
- Department of Medical Genetics, Haematology & Pathology
- Plus de détails
-
- ROYAUME-UNI
- South Glamorgan
- CARDIFF
- AML 14: A Randomised Trial for Patients with Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndrome Aged 60 or over (phase III) - UK
- Cardiff University School of Medicine
- Department of Medical Genetics, Haematology & Pathology
- Plus de détails
-
- ROYAUME-UNI
- Tayside
- DUNDEE
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study of the Efficacy and Safety of 2 Doses of Lenalidomide Versus Placebo in Red Blood Cell (RBC) Transfusion-Dependent Subjects With Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated With a Deletion (Del) 5q[31] Cytogenetic Abnormality (Phase III)
- Ninewells Hospital
- Department of Haematology
- Plus de détails
-
- ROYAUME-UNI
- West Yorkshire
- LEEDS
- NCRN133: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Of Deferasirox In Patients With Myelodysplastic Syndromes (Low/Int-1 Risk) And Transfusional Iron Overload - Telesto (Phase III)
- National Cancer Research Coordinating Centre
- Plus de détails
